CD4 and melanoma: 1) In summary, the results showed that ACT without a lymphodepleting regimen and with low doses of subcutaneous IL-2 was safe in heavily pre-treated patients with advanced melanoma 2) A higher percentage of CD4+ CD25+ CD127lowFoxp3+ T cells in the infused TIL population was associated with significantly shorter OS 3) Combining ACT with checkpoint inhibitors could potentiate the TIL effect, countering local immunodeficiency